Baba[19] |
Japan |
RCS |
78 |
|
66.6% |
怀疑/已知的恶性肿瘤 |
|
报告(礼物) |
|
Reported (malignant) |
|
|
Bilaçeroglu[22] |
Turkey |
PCS |
92 |
51 (mean) |
52.0% |
怀疑/已知的恶性肿瘤 |
|
Reported (absent) |
Reported |
|
Performed |
1 PNT 1 moderate bleeding |
Castella[10] |
Spain |
RCS |
45 |
|
69.0% |
怀疑/已知的恶性肿瘤 |
Reported |
Reported (absent) |
|
|
|
None |
Checkani[17] |
USA |
PCS |
37 |
|
51.0% |
Unselected |
|
Reported (absent) |
|
|
|
3 moderate bleeding |
Gasparini[4] |
Italy |
PCS |
435 |
|
59.1% |
Unselected |
|
报告(礼物) |
|
Reported (malignant/benign) |
Performed |
1 PNT |
Gupta[12] |
India |
PCS |
21 |
52 (mean) |
61.9% |
Unselected |
|
|
|
|
|
None |
Kawaraya[20] |
Japan |
RCS |
69 |
|
34.8% |
怀疑/已知的恶性肿瘤 |
|
|
|
Reported (malignant) |
|
|
Katis[11] |
Greece |
PCS |
37 |
44–78 |
62.1% |
Unselected |
|
Reported (absent) |
|
|
Performed |
None |
Iyoda[14] |
Japan |
RCS |
296 |
62.2 (mean) |
83.4% |
怀疑/已知的恶性肿瘤 |
|
报告(礼物) |
|
Reported (malignant) |
Performed |
|
Leiro-Fernández[6] |
Spain |
PCS |
36 |
65.6 (mean) |
30.6% |
Unselected |
|
报告(礼物) |
|
|
|
|
Pirozynski[21] |
Poland |
RCS |
24 |
|
58.3% |
怀疑/已知的恶性肿瘤 |
|
|
|
Reported (malignant) |
|
|
Reichenberger[13] |
Switzerland |
RCS |
152 |
63 (mean) |
35.5% |
Unselected |
|
|
|
Reported (malignant/benign) |
|
|
Roth[23] |
Norway |
RCS |
21 |
|
19.0% |
怀疑/已知的恶性肿瘤 |
|
Reported (absent) |
|
Reported (malignant) |
|
|
Schenk[9] |
USA |
PCS |
42 |
|
40.0% |
怀疑/已知的恶性肿瘤 |
|
|
|
Reported (malignant) |
|
None |
Shure[7] |
USA |
PCS |
42 |
46–77 |
52.4% |
怀疑/已知的恶性肿瘤 |
|
Reported (absent) |
|
Reported (malignant) |
Performed |
None |
Trisolini[5] |
Italy |
PCS |
218 |
66.7 (mean) |
65.0% |
Unselected |
Reported |
|
Reported |
Reported (malignant/benign) |
Performed |
4 PNT 4 major bleeding |
Wang[8] |
USA |
PCS |
20 |
|
55.0% |
Unselected |
|
Reported (absent) |
|
|
|
1 PNT |
Wang[18] |
USA |
PCS |
22 |
|
36.3% |
Unselected |
|
Reported (absent) |
|
|
Performed |
None |